Tetraphase Raises $45m To Advance Antibiotic Pipeline
Reportedly, Tetraphase will use the funds to advance its pipeline of antibiotics, into Phase 1 and Phase 2 clinical studies. The company’s TP-434, a broad spectrum intravenous (IV)
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
Findings from Abraxis BioScience phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab(R)) driven chemotherapy, nab-paclitaxel (Abraxane for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable